Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer

Cervical cancer ranks fourth globally in both incidence and mortality rates, making early diagnosis and treatment of great significance. For early-stage cervical cancer, surgery remains the primary treatment approach. According to the latest NCCN guidelines, patients with Stage IA2 or IB1 cervical cancer confirmed by cone biopsy who meet Concerv or SHAPE criteria no longer require type C/B hysterectomy. Instead, they may undergo type A hysterectomy with reduced surgical margins. However, patients with Stage IB2 or IIA1 tumors measuring 2-4 cm still require radical hysterectomy (type C). Radica

Trial Details

NCT ID
NCT07130240
Phase
PHASE2
Sponsor
Obstetrics & Gynecology Hospital of Fudan University
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Neoadjuvant Chemotherapy Combined with Immunotherapy
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • (1)Patients with FIGO 2018 stages IB2, IIA1 (2\< lesion ≤4 cm, confirmed by MRI); (2) Histologically confirmed cervical squamous cell carcinoma, ce…
  • (8) Adequate organ function as defined by the protocol, with test samples collected within 7 days before the start of study treatment.
  • (9) Participants voluntarily join the study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →